Drug Trial Radar · NCT03568383
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,832
Actual
Start
Jun 3, 2019
Primary completion
Nov 16, 2026
Study completion Nov 16, 2026
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Otsuka Pharmaceutical Development & Commercialization, Inc.
- First posted
- Jun 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases). High-risk HHCs are those with HIV or non-HIV immunosuppression, latent TB infection, and young children below the age of 5 years.
Conditions
- Tuberculosis, MDR
Interventions
Delamanid (DLM)Drug
Adults and children ≥30 kg: delamanid 200 mg orally once daily. Children ≥2.5 kg to \<30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits.
Isoniazid (INH)Drug
Adults and children ≥24 kg: INH 300 mg orally once daily. Children ≥2.5 kg to \<24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted.
Pyridoxine (vitamin B6)Dietary supplement
All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of participants with confirmed or probable active TB at any time between Day 0 and the week 96 study visitTime frame: Measured through Week 96
- Percent of participants who permanently discontinue randomized study drug (DLM or INH) due to a treatment-related adverse eventTime frame: Measured through Week 96
Locations
31 sites in 13 countries. Site status is shown where the registry gives one.
Gaborone CRS
Gaborone, South-East District, Botswana
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, Rio de Janeiro, Brazil
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
Port-au-Prince, Haiti
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, Haiti
Byramjee Jeejeebhoy Government Medical College (BJGMC) CRS
Pune, Maharashtra, India
YRG CARE CRS [Site ID: 32075]
Chennai, Tamil Nadu, India
Moi University Clinical Research Center (MUCRC) CRS
Eldoret, Rift Valley, Kenya
Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS
Kericho, Rift Valley, Kenya
Barranco CRS
Lima, Peru
San Miguel CRS
Lima, Peru
Socios En Salud Sucursal Perú CRS
Lima, Lima Province, Peru
TB HIV Innovations and Clinical Research Foundation Corp.
Silang, Cavite, Philippines
CAPRISA eThekwini CRS
Durban, South Africa
Soweto ACTG CRS
Johannesburg, Gauteng, South Africa
Wits Helen Joseph Hospital CRS (Wits HJH CRS)
Johannesburg, Gauteng, South Africa
Durban International Clinical Research Site CRS
Durban, KwaZulu-Natal, South Africa
PHRU Matlosana CRS
Klerksdorp, North West, South Africa
Rustenburg CRS
Rustenburg, North West, South Africa
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
Cape Town, Western Cape, South Africa
Task Applied Science (TASK) CRS
Cape Town, Western Cape, South Africa
University of Cape Town Lung (UCTL) CRS
Cape Town, Western Cape, South Africa
South African Tuberculosis Vaccine Initiative (SATVI) CRS
Cape Town, Western Cape, South Africa
Kilimanjaro Christian Medical Centre (KCMC)
Moshi, Tanzania
Chiangrai Prachanukroh Hospital NICHD CRS
Chiang Mai, Thailand
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
Pathum Wan, Bangkok, Thailand
Siriraj Hospital ,Mahidol University NICHD CRS
Bangkok, Bangkoknoi, Thailand
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site
Kampala, Uganda
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
Kampala, Uganda
National Lung Hospital CRS (Site ID: 32483)
Vĩnh Phúc, Hanoi, Vietnam
Vietnam-University of Sydney CRS Site# 32495
Ho Chi Minh City, Vietnam, Vietnam
Milton Park CRS
Milton Park, Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.